Up­dat­ed: Striv­ing for 2023 launch, Pfiz­er touts topline PhI­II win for an­oth­er mass mar­ket vac­cine

One of the vac­cines that Pfiz­er has pegged for a 2023 launch has hit the mark in Phase III, set­ting up a fil­ing by the end of the year.

MenABCWY, as the shot is known, is a pen­tava­lent meningo­coc­cal vac­cine can­di­date that com­bines two ex­ist­ing Pfiz­er vac­cines — Tru­men­ba and Ni­men­rix — in one. By for­mu­lat­ing them to­geth­er, the com­pa­ny says it could sim­pli­fy the vac­ci­na­tion sched­ule with one vac­cine that pro­vides the broad­est serogroup cov­er­age of any out there.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER